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Background: Primary dysmenorrhea is a common and sometimes disabling condition. In recent years, some
studies aimed to improve the treatment of dysmenorrhea, and therefore, introduced several therapeutic measures.
This study was designed to compare the analgesic effect of iron chip containing heat wrap with ibuprofen for the
treatment of primary dysmenorrhea.
Methods: In this randomized (IRCT201107187038N2) controlled trial, 147 students (18–30 years old) with the
diagnosis of primary dysmenorrhea were enrolled considering the CONSORT guideline. Screening for primary
dysmenorrhea was done by a two-question screening tool. The participants were randomly assigned into one of
the intervention groups (heat Patch and ibuprofen). Data regarding the severity and emotional impact of the pain
were recorded by a shortened version of McGill Pain Questionnaire (SF-MPQ). Student's t test was used for statistical
analysis.
Results: The maximum and minimum pain severities were observed at 2 and 24 hours in both groups. The severity
of sensual pain at 8, 12, and 24 hours was non-significantly less in the heat Patch group. There was also no
significant difference between the groups regarding the emotional impact of pain at the first 2, 4, 8, 12 and
12 hours of menstruation.
Conclusions: Heat patch containing Iron chip has comparable analgesic effects to ibuprofen and can possibly be
used for primary dysmenorrhea.
Trial registration: IRCT201107187038N2Background
Primary dysmenorrhea is a common and sometimes dis-
abling condition among women of childbearing age [1]
The prevalence of dysmenorrhea worldwide is, with
rates ranging from 15.8-89.5%, with higher prevalence
rates reported in adolescent populations [2] The preva-
lence is estimated to be 72% among menstruating
women in Iran [3]. Dysmenorrhea is caused by excessive
uterine contraction, interruption of blood supply, and
production of prostaglandins. During the first 24 hours
of menstruation, endometrial vessels contract, and blood* Correspondence: fkermansaravi@yahoo.com
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distribution, and reproduction in any mediumsupply to the endometrial tissues is reduced, which
eventually leads to necrosis of the endometrial layer [4].
Pain and lower abdominal cramps are among the most
common causes of gynaecological referrals [5-7]. Dys-
menorrhea is sometimes associated with nausea, vomit-
ing, diarrhea, fatigue, fever, headache [6,8,9], back pain,
and dizziness [1].
Factors contributing to dysmenorrhea include the age
of early menarche, increased menstrual bleeding, alcohol
and tobacco use, low socioeconomic status, obesity, and
depression [10]. Childbirth decreases the likelihood of
dysmenorrhea because of the reduced number of adren-
ergic receptors in the uterus [4-11]. Dysmenorrhea is the
leading cause of absence from school and work and has
a negative impact on the quality of life and generalntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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the family's economic status [6].
In recent years, some researchers have aimed to im-
prove the treatment of dysmenorrhea. Several thera-
peutic measures have been introduced, including the use
of non-steroidal anti-inflammatory drugs (NSAIDs) as
first-line therapy [15], and some other measures such as
local heat [1,7]. The analgesic effect of local heat is simi-
lar to the electrical cutaneous stimulation of nerves,
which is explained by the gate-control theory of pain or
by central alteration of the pain threshold [16,17].
Thermal therapy has traditionally been used to treat
dysmenorrhea [16,17]. Usual forms of thermal therapy
such as hot water bottles and electric pads may be
annoying and may interfere with daily life. Although oral
medications are effective, they can cause constipation
and other gastrointestinal symptoms and should be
administered only if justified by the severity of pain [17].
For instance, ibuprofen can cause gastrointestinal inflam-
mation or bleeding, skin rash, pruritus, tinnitus, dizzi-
ness, and renal or hepatic complications [18].
Even though pharmacological treatment of dysmenor-
rhea is usually successful, the failure rate is about 20–
25% [6]. NSAIDs are the first choice of treatment, but
sometimes side effects such as adverse gastrointestinalFigure 1 CONSORT flow diagram.symptoms oblige patients to look for alternative treat-
ments. Although heat (in different forms such as a hot
bag, towel, or bottle) has traditionally been used to ease
pain in many cultures, its utilization is currently limited
because of the lack of interest among youth in trad-
itional remedies and because of the limited research
undertaken to evaluate its effectiveness.
We aimed to compare a non-pharmaceutical, non-
invasive treatment (heat wrap) with a routine medication
(ibuprofen) for the treatment of treat dysmenorrhea.
Methods
This randomized controlled trial (number IRCT201
107187038N2) was approved by the Ethical Committee
of Zahedan University of Medical Sciences and was
undertaken in accordance with CONSORT guidelines
(Figure 1).
From December 2007 to June 2008, 147 students res-
iding in the dormitory of Zahedan University in south-
East Iran were enrolled in the study.
Inclusion criteria were age 18 to 30 years, and dys-
menorrhea in young women within the first 2 years of
the onset of menstruation and all had regular menstrual
cycles and good general health, moderate and severe
cramps.
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rate of endometriosis is high [19] and an history of endo-
metriosis can justify pain also in patients who were surgi-
cally treated, both with eventual Oral estroprogestins after
primary surgery and without adjuvant oral therapy post
surgery [20], or other any underlying illness or cause. The
students were randomly probably sampling assigned into
ibuprofen and heat patch groups.
The students were asked two questions (based on
suggestions from The Association of Women's Health,
Obstetric and Neonatal Nurses) to screen for dysmen-
orrhea: 1) Have you ever experienced pelvic pain or
cramps during or around menstrual bleeding? and 2)
Was the pain bearable for you?
Of the 186 women initially enrolled in our study, 39
were excluded. Exclusion criteria were: a history of co-
morbidities (e.g., cardiovascular, renal, hepatic, or pulmon-
ary disease), coagulopathy, diabetes mellitus, anaemia,
gastrointestinal bleeding, immunological disorder, malig-
nancy, psychiatric illness requiring therapeutic interven-
tion, use of contraceptive pills, smoking, history of
childbirth, professional athletic activity, lower abdominal
scars, body mass index (BMI) >30 kg/m2, history of vagin-
itis, and recent death or stressful event in the immediate
family.
Abdominal circumference and BMI were measured be-
fore the intervention. In the heat patch group (n = 72), a
7 × 12 cm patch (Mahdad Afruz Co., Iran) was supplied
to the participants to place in their underwear when
menstrual bleeding started. The students were trained in
the use of the patch. In the ibuprofen group (n = 75),
ibuprofen was prescribed (400 mg, orally every 8 hours,
as required).
The students were asked to complete two question-
naires. One questionnaire collected demographic data,
and the other was a shortened revision of the McGill
Pain Questionnaire (SF-MPQ). The students were given
instruction on completing the pain questionnaire. The
severity of pain was assessed using 15 descriptive
phrases. Eleven phrases described sensory aspects of
pain giving a score from 0 to 33 points, and four phrases
described emotional aspects of pain giving a score from
0 to 12 points. Current and overall pain severity scores
were indicated using the visual analog scale (0–100 and
0–5, respectively). Higher numbers indicated moreTable 1 Demographic characteristic two groups
BMI(weight/high2) Abdomen circumference(cm)
Mean SD Mean SD
2.59 20.96 8.66 76
3.26 20.61 9.71 76
P > 0.05 P > 0.05severe pain. Pain was measured at 2, 4, 8, 12, and
24 hours after the onset of menstruation.
The McGill questionnaire is a reliable tool, with
proven validity and reliability, which has been recom-
mended for clinical investigations in the Iranian popu-
lation [21]. This questionnaire has been also previously
been used for the assessment of pain in dysmenorrhea
[22]. The validity of McGill questionnaire was evalu-
ated in 1975 by Melzack [23], and the validity of the
SF-MPQ has been evaluated for obstetric, postopera-
tive, physical therapy, and dentistry patients. The shor-
tened version has been compared with the standard
McGill questionnaire and a significant correlation be-
tween the two has been demonstrated [24].
SPSS software version 13 was used for statistical ana-
lysis. The student's t test was used to compare measure-
ments between the groups.
Results
Demographic characteristic
The mean age of the students in the heat Patch and
ibuprofen groups was 22.66 and 20.92 years, respect-
ively (P > 0.05). There was also no significant differ-
ence between the groups regarding the marital and
socio-economical status, mean body mass index, and
abdominal circumference75 (93.1%) of the students in
the heat patch group and72 (90.7%) of the students in
the ibuprofen group were married (Table 1).
Pain domains
The maximum and minimum pain severities were
observed at 2 and 24 hours after menstruation in both
groups. The severity of sensual pain at 8, 12, and
24 hours after menstruation was non-significantly less in
the heat Patch group. The severity of emotional pain im-
pact and final assessment mean of the total pain rating
at 4, 8, 12, and 24 hours were not significantly different
(Tables 2, Additional file 1: Table S3).
Discussion
In this study, the heat wrap group had milder pain dur-
ing the first 24 hours of menstruation compared with
the ibuprofen group, but this difference was not statisti-
cally significant.Age(year)
Mean SD
.88 2.91 22.66 Heat pach
.96 2.04 20.92 Ibuprofen
P > 0.05 T-TEST
Table 2 Comparison score (mean± SD) pain domains
McGill primary dysmenorrheal in two groups





SD Mean SD Mean
Severity sensual pain (0–33) 6.84 5.55 6.81 5.51 P > 0.05
Severity emotional pain (0–12) 2.94 3.13 2.60 2.63 P > 0.05
Severity Current pain (0–100) 32.91 26.97 36.41 26.54 P > 0.05
Total pain (0–5) 2.72 3.57 1.93 1.63 P > 0.05
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pharmacological treatments for dysmenorrhea [25,26].
However, only a few studies have addressed this issue.
Akin and colleagues showed that local heat was as ef-
fective as ibuprofen for the treatment of dysmenorrhea
[16,27]. However, local heat was not shown to be effective
in other reports [12]. A new thermogenic device has also
been evaluated which provides a constant temperature of
40 °C for 8 hours through the oxidation of iron chips,
which does not interfere with daily activities and is effect-
ive, safe, and reasonably priced [13].
In our study, pain was measured using the SF-MPQ.
This questionnaire has three main sections and contains
a number of phrases to assess the individual’s pain per-
ception (sensual and emotional). Cultural differences,
socioeconomic factors, the availability of support, and
the individual’s personality play an important role in pain
perception. The McGill questionnaire takes these into
consideration. Bajaj and colleagues also used this tool to
compare the effects of local heat on the pain threshold of
women with and without dysmenorrhea and found that
dysmenorrhea pain could be soothed by applying local
heat, and that pressure on the abdomen and back
increased the pain threshold [22]. In our study, we ap-
plied heat to only one point. We found that the total pain
rating was less in the local heat group, although there
were no significant differences between groups.
There were noticeable differences in the emotional
aspects of pain during the first 12 hours after the onset
of menstruation, but these were not statistically signifi-
cant. In this the current pain score appears was low in
Ibuprofen group than in heat patch group at 8 h, because
the maximum effectiveness pad is 8 hours. But This dif-
ference was not significant (t = 1.18, p = 0.24). With a lar-
ger sample size, this difference may have become
significant. Akin and colleagues compared the effective-
ness of oral ibuprofen or placebo with and without local
heat, and observed that ibuprofen with and without local
heat was more effective than placebo. Local heat (non-
thermal wrap) was also found to be more effective than
placebo. The analgesic effect was significantly faster in
the ibuprofen plus local heat group than in the other
groups [28].There are some notable differences between our study
and that by Akin and colleagues. We used an 84 cm2
patch and the multidimensional McGill pain score tool,
and Akin used a 180 cm2 wrap and a one-dimensional
visual analog pain scale, but these differences should not
affect the results. Both studies applied local heat to the
same area of the abdomen.
Some of our results are consistent with those of Bajaj
and colleagues, who reported that a towel containing an
iron chip was more effective in reducing back pain than
ibuprofen and acetaminophen on the first, third, and
fourth days of menstruation, which was probably due to
the large surface area of application and to the area
where the heat was applied. This effect could be due to
pressure-sensitive points on the back. In comparison
with acetaminophen, these towels have been shown to
be more effective in the treatment of dysmenorrhea at 3,
4, 5, and 6 hours after the onset of menstruation [27].
Some studies have shown that transcutaneous electrical
nerve simulation, which works by the same mechanism
as local heat, can be effective for the treatment of dys-
menorrhea. This method places stimulatory electrodes
over the lumbar and sacral areas, together with local
heat. Further investigation of this method is needed [29].
Heat wraps have also been compared with acetamino-
phen, and were found to be significantly more effective
[27].
Although pharmacotherapy can be used to treat dys-
menorrhea, it is not effective in 20–25% of patients [6].
Using NSAID drugs as first-line treatment may be lim-
ited because of adverse reactions such as gastrointestinal
side effects, which mandates the selection of alternative
therapeutic modalities.
A retrospective study of the complications of dysmen-
orrhea showed that 98% of teenagers had used one or
more methods to control the pain [30]. In another study,
all participants had used local heat to treat the pain [31].
The physiological effects of thermal therapy act via ner-
vous, vascular, and biophysical pathways. Analgesia via
the nervous pathway can be explained by Melzack's
gate-control theory of pain. [25,26]. This theory provides
a logical explanation for the use of pain control mea-
sures such as local heat, cold, pressure, massage, and
electrical stimulation [24]. These findings are compatible
with the findings of Akin and Nadler [16,27,28].
Heat induced vascular reactions will increase the blood
flow to an area, resulting in the dilution of intravascular
prostaglandins, bradykinin, and histamine. These mole-
cules are among the most potent pain inducing mole-
cules. Increased blood flow also improves tissue
oxygenation [32]. Local heat applied to the upper abdo-
men increases gastrointestinal motility and has a relax-
ing effect on the uterus. Previous studies have provided
explanations for this mechanism [16]. NSIADs are the
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heat is as effective as NSIADs [16], but users should be
aware of potential side effects of NSAIDs.
Few studies have addressed the use of ibuprofen for
dysmenorrhea in Iran [33-35]. Our study is the first
which compares the effectiveness of this medication with
local heat. There are some studies from other countries
which evaluate NSAIDs for the treatment of dysmenor-
rhea, but according to a review study, there is little or
no evidence regarding the safety and adverse effects of
these drugs [36]. We found that this apparently insignifi-
cant result could open a new scenario for women who
can’t be treated by FANS (e.g. allergy, haemorrhagic
diathesis, gastric ulcera).
Our study has some limitations, including the effects
of variations in the thickness of lower abdominal adipose
tissue which acts as a thermal insulator [37 However, ab-
dominal circumference and BMI were similar between
groups. Blinded, double blinded, or triple blinded treat-
ments were not possible in our study since the thera-
peutic measures used were obvious. The pain threshold
varied among subjects, because people experience pain
differently in different emotional states, which was be-
yond the control of the investigators. We excluded
women with a history of psychiatric or personality disor-
ders and those who were grieving to address this issue.Conclusions
The main purpose of any treatment is to provide the most
effective and less harmful therapeutic methods for the
patients. We introduced a new tool for pain control which
can possibly replace ibuprofen in the treatment of primary
dysmenorrhea. We showed that probably heat Patch con-
taining iron chip has comparable analgesic effects to ibu-
profen, Because there wasn't significant. And as a
complementary and non-drug methods may be proposed.Additional file
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